HC Wainwright Initiates Redhill Biopharma At Buy

Analysts at HC Wainwright initiated coverage on

with a Buy rating. The target price for Redhill Biopharma is set to $23. Redhill Biopharma shares have dropped 0.29% over the past 52 weeks, while the S&P 500 index has surged 11.47% in the same period. Redhill Biopharma's shares rose 3.73% to $14.17 in pre-market trading.